as 12-20-2024 3:41pm EST
Renovaro Inc is a biopharmaceutical company. It is engaged in developing new immunotherapies to combat cancer and developing a predicative artificial intelligence-based diagnostic methodology for the use of earlier cancer detection.
Founded: | 2011 | Country: | United States |
Employees: | N/A | City: | SUITE 906 LOS ANGELES |
Market Cap: | 279.3M | IPO Year: | N/A |
Target Price: | N/A | AVG Volume (30 days): | 1.5M |
Analyst Decision: | N/A | Number of Analysts: | N/A |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.97 | EPS Growth: | N/A |
52 Week Low/High: | $0.40 - $5.25 | Next Earning Date: | 02-12-2025 |
Revenue: | N/A | Revenue Growth: | N/A |
Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
RENB Breaking Stock News: Dive into RENB Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
GlobeNewswire
2 days ago
GlobeNewswire
2 months ago
GlobeNewswire
2 months ago
GlobeNewswire
2 months ago
GlobeNewswire
3 months ago
GlobeNewswire
3 months ago
GlobeNewswire
3 months ago
The information presented on this page, "RENB Renovaro Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.